Henning Gruell

Oct 13, 2024 | nature.com | Henning Gruell |Philipp Schommers

In a recent article in Science, Leon Weinberger and colleagues report on successful proof-of-concept studies of a novel strategy to control HIV-1 infection by using interfering viral particles.1 This approach radically differs from small-molecule antiretroviral drugs that can prevent disease progression and transmission by inhibiting viral replication but require life-long use.

Nov 12, 2023 | nature.com | Philipp Schommers |Dae Sung Kim |Christoph Kreer |Henning Gruell |Elena Knops |Timo Wolf | +10 more

AbstractHuman immunodeficiency virus type 1 (HIV-1)-neutralizing antibodies (nAbs) that prevent infection are the main goal of HIV vaccine discovery. But as no nAb-eliciting vaccines are yet available, only data from HIV-1 neutralizers—persons with HIV-1 who naturally develop broad and potent nAbs—can inform about the dynamics and durability of nAb responses in humans, knowledge which is crucial for the design of future HIV-1 vaccine regimens.